InMed Pharmaceuticals Inc.
INM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728328
In the last 90 days, InMed Pharmaceuticals Inc. insiders filed 4 open-market purchases and 0 sales; 20 institutions reported holding it in 13F filings for Q2 2026, worth $4.18M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding InMed Pharmaceuticals Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 15 | 14 | −1 |
| Shares | 133.2K | 116.0K | −17.2K (−12.9%) |
| Value | $876.9K | $234.4K | −$642.5K (−73.3%) |
New holders (3)
Institutions that held InMed Pharmaceuticals Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 17,724 | $36.0K | 0.00% |
| BlackRock Inc. | 50 | $101 | 0.00% |
| Advisory Services Network, LLC | 6 | $12 | 0.00% |
Sold out (4)
Institutions that held InMed Pharmaceuticals Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Sabby Management, LLC | 15,284 | $101.0K |
| Millennium Management LLC | 13,922 | $91.0K |
| Bank of America Corp | 6,770 | $45.0K |
| Tower Research Capital LLC (TRC) | 1,067 | $7.00K |